Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Merck's (MRK -2.9%) Tredaptive (Cordaptive) cholesterol treatment failed to meet its primary...

  • Thursday, December 20, 2012, 9:00 AM ET
    Merck's (MRK -2.9%) Tredaptive (Cordaptive) cholesterol treatment failed to meet its primary goal in a massive study of 25,673 patients. The drug didn't significantly cut the risk of coronary deaths, non-fatal heart attacks, strokes or revascularizations compared with statin therapy. Merck will end its bid to for regulatory approval of Tredaptive in the U.S.; the drug is sold in 40 countries and had sales of $13M in Q1-Q3. (PR)
Track new comments on this story

This news story has 1 comment:

  •  
    Of course we'll need to see the final results (probably to be presented at ACC in March 2013), but this probably means the end of the line for niacin treatment for dyslipidemia and maybe also for HDL-C-raising therapies in general. This result likely validates the AIM HIGH result and may also validate the decisions by other pharmas to discontinue CETP inhibitor (HDL-C-raising) programs.
    20 Dec 2012, 04:32 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »